Archive: October 2024
Feature Article
Refining the Standard of Care in Immune Thrombotic Thrombocytopenic Purpura
Abstract: Acute immune thrombotic thrombocytopenic purpura (iTTP) is a medical emergency. In the setting of any thrombotic microangiopathy (TMA), blood should be drawn to measure ADAMTS13 […]
Feature Article
Management Options for Node-Positive Muscle-Invasive Bladder Cancer
Abstract: Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence […]
Prostate Cancer In Focus
Management of Oligometastatic Hormone-Sensitive Prostate Cancer
H&O How is oligometastatic defined in the context of hormone-sensitive prostate cancer (HSPC)? PT We used to make a binary distinction between localized HSPC, which is […]
Advances in LLM
Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?
H&O What is luspatercept, and how does it work for patients who have anemia associated with transfusion-dependent low-risk myelodysplastic syndromes (LR-MDS)? GCM Luspatercept (Reblozyl, Celgene/BMS) is […]
Letter From the Editor
Letter From the Editor: Incentive Planning
Entering the field of oncology means caring for patients who may die of their disease, and it takes a certain type of person to do this […]
CLL
Doublet vs Triplet Combinations for Frontline Treatment of Chronic Lymphocytic Leukemia
H&O What are the advantages of doublet combinations over single-agent Bruton tyrosine kinase (BTK) inhibitor therapy in the frontline therapy of chronic lymphocytic leukemia (CLL)? NJ […]
CRC in Focus
The Emerging Role of Immunotherapy-Based Strategies in Nonmetastatic Colorectal Cancer
H&O What makes immunotherapy an appealing option for patients with nonmetastatic colorectal cancer (CRC)? MC Immunotherapy has become important because it is more effective than chemotherapy […]
Advances in Drug Development
The Global Cardio-Oncology Registry
H&O How did the field of cardio-oncology come about? DS There are about 20 million cancer survivors in the United States. With significant improvements in immunotherapy, […]